VBI applies its eVLP platform to develop Zika vaccine

摘要

VBI Vaccines, a US biopharmaceutical firm, has applied its clinical-stage eVLP (enveloped viruslike particle) platform to the development of a vaccine candidate to prevent Zika. Jeff Baxter, VBI's CEO, said the firm is using its eVLP platform, and the expertise gained while developing its cytomegalovirus (a virus in the herpes family) vaccine candidate, now in Phase I clinical trials, as it advances this programme.